TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10 - Mediated suppression of antitumor immunity

Dusan Bogunovic, Olivier Manches, Emmanuelle Godefroy, Alice Yewdall, Anne Gallois, Andres M. Salazar, Isabelle Marie, David E. Levy, Nina Bhardwaj

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Toll-like receptor (TLR) agonists are promising adjuvants for immune therapy of cancer, but their potential efficacy as single or combinatorial agents has yet to be fully evaluated. Here, we report that among all TLR agonists tested, dendritic cells (DC) stimulated with the TLR3 agonist polyI:C displayed the strongest activity in stimulating proinflammatory responses and the production of melanoma antigen-specific CD8+ T cells. Simultaneous treatment with TLR7/8 agonists further improved these responses, but the inclusion of bacterial lipopolysaccharide (LPS), a TLR4 agonist, suppressed proinflammatory cytokine production. This inhibition was contingent upon rapid induction of the suppressive cytokine interleukin (IL)-10 by LPS, leading to dysregulated immune responses and it could be reversed by signal transducers and activators of transcription 3 knockdown, p38 blockade or antibodies to IL-10 and its receptor. Our findings show how certain TLR agonist combinations can enhance or limit DC responses associated with antitumor immunity, through their relative ability to induce IL-10 pathways that are immune suppressive.

Original languageEnglish
Pages (from-to)5467-5476
Number of pages10
JournalCancer Research
Volume71
Issue number16
DOIs
StatePublished - 15 Aug 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10 - Mediated suppression of antitumor immunity'. Together they form a unique fingerprint.

Cite this